system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Antibiotics, Antineoplastic, Antineoplastic Agents, Apoptosis, Blotting, Western, Cell Proliferation, Chordoma, Cisplatin, Doxorubicin, Furans, Humans, Phosphatidylinositol 3-Kinases, Protein Kinase Inhibitors, Protein Kinases, Proto-Oncogene Proteins c-akt, Pyridines, Pyrimidines, TOR Serine-Threonine Kinases, Tumor Cells, Cultured.
user
Does combination of PI3K/mTOR inhibition demonstrate efficacy in human chordoma? Context: Chordomas are rare tumors of the axial skeleton for which surgical resection remains the most reliable means of cure. PI-103 is a inhibitor of PI3K/AKT and mTOR activation. This study aims to determine whether the PI3K/mTOR pathway was active in chordomas and whether their inhibition could lead to decreased proliferation and increased apoptosis. Thirteen human chordoma were tested for activation of the PI3K/mTOR pathway. The human chordoma cell line UCH-1 was treated with increasing doses of PI-103. Inhibition of AKT and mTOR was examined and assays assessing proliferation and apoptosis were performed. The chordoma specimen demonstrated activation of the PI3K/mTOR pathway. PI-103 inhibited the AKT and mTOR activation in the UCH-1 cell line. PI-103 inhibited proliferation and induced apoptosis in UCH-1.
assistant
The PI3K/AKT and mTOR signaling pathway is constitutively activated in chordoma. PI-103 decreases proliferation and induces apoptosis in the UCH-1 via inhibition of the PI3K/mTOR pathway. Final Decision: yes